Stenabolic and its Powerful Effects in Research

Stenabolic is not a SARM but rather a potent non-addictive Nootropic in the REV-ERB agonist category. REV-ERB proteins regulate the body’s core clock and circadian rhythm, they alter the expression of genes involved in lipid and glucose metabolism, cartilage breakdown, and scientists are studying their ability to reduce the risk of heart disease via atherosclerosis.

Stenabolic Research

Several studies suggest that Stenabolic and other REV-ERB agonists may maintain wakefulness in pathological conditions that affect sleep. SR9009 is able to induce wakefulness at different times during the light period and maintained its efficacy even when administered throughout the day. 

SR9009 has demonstrated in vitro and in vivo to increase basal oxygen consumption, decrease lipogenesis, increase mitochondrial content of muscle tissue, decrease fat storage, and increase glucose and fatty acid oxidation in skeletal muscles. These effects have increased research on this compound for several metabolic disorders.

Stenabolic SR9009 Research Continued

REV-ERB proteins have been shown to function as transcription repressors in articular cartilage. Chondrocytes with known catabolic agents cause the induction of REV-ERB alpha as a defense mechanism, whereas stimulation with anabolic agents decreases REV-ERB activity. 

Overexpression of REV-ERB activity is shown to decrease matrix-degrading enzymes like matrix metalloproteinase 13 and aggrecanase.

Recent studies have also linked REV-ERB proteins to reduced risk of atherosclerosis. REV-ERB knockout mice have shown increased atherosclerosis, while atherosclerotic mice given SR9009 twice per day showed improvement in atherosclerosclerotic lesions as well as significant improvements in plasma lipid levels.

Stenabolic SR 9009 Research: Oral Squamous Cell Carcinoma (OSCC)

Animal studies related to OSCC  were designed by recent researchers. Papagerakis and colleagues designed a rhythmic drug release according to circadian time and studied resetting disrupted circadian rhythm (CR) to minimize drug-related toxicities and enhance treatment efficiency in OSCC. 

Previous studies have also indicated potential therapeutic benefits of antacid medication in head and neck squamous cell carcinoma. To evaluate the chemotherapeutic effects of a circadian clock regulating SR9009 and/or a proton pump inhibitor (Esomeprazole) in OSCC, a study was conducted using HPV- (FaDu) and HPV+ (2A3) OSCC cell lines.

Stenabolic SR 9009 Study Analysis: OSCC

The study analyzed the expression of core clock genes BMAL1 and REV-ERBα in tumor samples generated in vivo by inoculating mice with Eso-treated and untreated OSCC cell lines to better understand stenabolic’s benefits with CR. 

The results showed significant differences in gene expression between the two groups, suggesting different mechanisms of action for HPV+ and HPV- OSCC.

In vitro assays using the same OSCC cell lines demonstrated that SR9009 and Esomeprazole, alone and in combination, inhibited cell viability, proliferation, and migration. The combination showed strong synergistic side effects, resulting in circadian oscillation of gene expression levels for 24-hour cycles after administration.

To optimize anti-cancer effects and minimize toxicity, gene expression profiles were evaluated at various time points after SR9009 Stenabolic administration. The findings suggest that the circadian clock and SR9009 stenabolic are closely linked to OSCC outcomes.

Additional research is needed to test these Stenabolic SR9009 in pre-clinical animal models and determine the optimal time of Stenabolic SR9009 half-life and delivery. Overall, these results support the development of personalized therapeutic approaches for OSCC based on circadians and clock gene expression.

Using Stenabolic To Replicate Precise Data in Research on Thoroughbreds

SR9009 and SR9011 are synthetic agonists that pharmacologically target REV-ERB receptors as metabolic modulators. To detect these compounds in equine plasma, researchers developed and validated a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. 

First, plasma samples were pretreated with methanol for protein precipitation and then loaded onto an ACQUITY ultra-performance liquid chromatography high-strength silica C18 column for chromatographic separation.  

The mobile phase comprised of 5-mM ammonium formate in distilled water and 0.1% formic acid in acetonitrile, and a gradient elution was used at a flow rate of 0.25 ml/min. Mass spectrometry was also detected. 

The researchers evaluated the method’s linearity, lower limit of quantification, intra- and inter-day precision, accuracy, matrix effect, recovery, and stability. They found that the method was accurate and reproducible for quantifying SR9009 and SR9011.  

The developed method was successfully applied to plasma samples of thoroughbreds that were injected intramuscularly with SR9009. Further testing is needed as there were no side effects reported from the research above after thoroughbred testing, only methods used to test and replicate the above study parameters were noted.

More Circadian Rhythm Research and Animal Studies

What Benefits of Stenabolic Are Researchers Studying?

1. Wakefulness

2. Oxidation of fatty acids and glucose, and fat storage effects, effects of a high cholesterol diet

3. Skeletal muscle mitochondria content

4. Recovery of connective tissue

5. Arterial plaque/atherosclerosis

6. Body fat loss or gain

7. Insulin sensitivity and correlations related to magnesium oxide

Stenabolic is also available in pure powder form here

AT THIS TIME, STENABOLIC / SR9009 IS ONLY APPROVED FOR LABORATORY RESEARCH AND IS NOT SOLD FOR HUMAN CONSUMPTION.

Abuse Warning